QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
QuidelOrtho Corp
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)
Close on Oct 19, 2026
- Market cap
- $871.51M
- P/E (TTM)
- –
- Dividend yield
- –
QuidelOrtho Corp revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $1.43B | $1.41B | $1.49B | $1.50B | $1.55B | $1.59B | $1.62B | $1.67B | $1.70B | $1.73B | $1.88B | $2.05B | 53.4% | -8.1% |
| EMEA | $368.20M | $364.30M | $360.70M | $353.90M | $346.10M | $339.90M | $335.80M | $340.80M | $331.30M | $330.80M | $327.30M | $312.20M | 13.8% | +6.4% |
| China | $307.60M | $323.20M | $334.70M | $329.90M | $325.70M | $323.90M | $325.00M | – | – | – | – | – | 11.5% | -5.6% |
| China | – | – | – | – | – | – | – | $315.20M | $315.90M | $315.60M | $310.10M | $289.90M | – | – |
| Other | – | – | – | – | – | – | – | $491.20M | $487.90M | $488.10M | $483.30M | $473.60M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of QuidelOrtho's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.